Talphera Inc. Achieves 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial, On Track for Year-End Completion
Reuters
Aug 25
<a href="https://laohu8.com/S/TLPH">Talphera Inc.</a> Achieves 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial, On Track for Year-End Completion
Talphera Inc., a specialty pharmaceutical company, has announced a significant milestone in its NEPHRO CRRT pivotal trial, with the enrollment of 17 patients in the 70-patient study. This achievement marks approximately 25% of the trial's enrollment and is a critical step towards the completion of the study, which is projected by the end of 2025. The recent acceleration in patient recruitment is attributed to the re-launch of the study with new target profile clinical sites and principal investigators, contributing to over 90% of enrolled patients coming from these new sites. This milestone also fulfills a condition necessary to proceed with the second tranche of a three-tranche financing plan initiated in March 2025. The results of the trial are expected to be presented in the future, as the study progresses towards its planned completion.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Talphera Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF57699) on August 25, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.